Related Experiment Video
Updated: Feb 19, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.6K
Tofacitinib: A New Oral Therapy for Psoriasis
Alexandra Azevedo1, Tiago Torres2,3
1Department of Dermatology, Centro Hospitalar do Porto, Rua D. Manuel II, S/N, ex-CICAP, 4099-001, Porto, Portugal.
Clinical Drug Investigation
|November 3, 2017
Summary
Tofacitinib, an oral JAK inhibitor, offers sustained efficacy and good tolerability for moderate-to-severe chronic plaque psoriasis. This oral treatment addresses unmet needs in psoriasis therapy, potentially improving patient outcomes.
Area of Science:
- Immunodermatology
- Pharmacology
Background:
- Psoriasis is a chronic, immune-mediated disease with significant physical and emotional burden.
- Biologic therapies have advanced psoriasis treatment, yet unmet needs persist regarding long-term efficacy, safety, and cost.
- Understanding intracellular metabolic pathways in immune response has led to targeted therapies.
Purpose of the Study:
- To evaluate the efficacy and tolerability of tofacitinib, an oral Janus kinase (JAK) inhibitor, for moderate-to-severe chronic plaque psoriasis.
- To assess the long-term outcomes of tofacitinib treatment in psoriasis patients.
Main Methods:
- Phase II and III clinical trials were conducted to gather data on tofacitinib's performance.
- The study focused on the JAK/STAT pathway's role in pro-inflammatory gene upregulation in psoriasis.
Main Results:
- Tofacitinib demonstrated sustained efficacy for up to two years in patients with moderate-to-severe chronic plaque psoriasis.
- The treatment was found to be well-tolerated, with a favorable safety profile.
- Oral administration offers convenience without the organ toxicity associated with conventional oral treatments.
Conclusions:
- Tofacitinib presents a well-tolerated and effective oral treatment option for moderate-to-severe chronic plaque psoriasis.
- Its sustained efficacy and convenient administration position it as a valuable addition to psoriasis treatment algorithms.
- This JAK inhibitor addresses several unmet needs in current psoriasis management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
542
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
542
01:29Inflammatory Bowel Disease IV: Pharmacological Management
817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
817
01:29Drugs for Treatment of Ulcerative Colitis in IBD
549
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
549
01:20The JAK-STAT Signaling Pathway
13.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.2K